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Abstract
Development and Phase 3 testing of the most advanced malaria vaccine, RTS,S/AS01, indicates that malaria vaccine
R&D is moving into a new phase. Field trials of several research malaria vaccines have also confirmed that it is
possible to impact the host-parasite relationship through vaccine-induced immune responses to multiple antigenic
targets using different platforms. Other approaches have been appropriately tested but turned out to be
disappointing after clinical evaluation.
As the malaria community considers the potential role of a first-generation malaria vaccine in malaria control
efforts, it is an apposite time to carefully document terminated and ongoing malaria vaccine research projects so
that lessons learned can be applied to increase the chances of success for second-generation malaria vaccines over
the next 10 years.
The most comprehensive resource of malaria vaccine projects is a spreadsheet compiled by WHO thanks to the
input from funding agencies, sponsors and investigators worldwide. This spreadsheet, available from WHO’s
website, is known as “the rainbow table”. By summarizing the published and some unpublished information
available for each project on the rainbow table, the most comprehensive review of malaria vaccine projects to be
published in the last several years is provided below.
Background
Few recent malaria vaccine review articles have
attempted a comprehensive outline of all clinical trials
that have occurred globally. The field has grown to such
an extent that it is now very difficult to summarize all
projects in a single review. The increase in funding over
the last 10 years has allowed over 40 vaccine projects to
reach the clinical trial stage. This manuscript is a com-
prehensive review of malaria vaccine clinical projects
written in recent years, though even here it is possible
that not every project has been included.
WHO compiles the “rainbow table” spreadsheet, a
comprehensive publicly available collation of global
malaria vaccine project activity with input from funders,
sponsors and investigators [1]. For this review, published
papers related to each project from the rainbow table
were obtained, and clinical trial registry information and
conference abstracts were read, where papers are not
yet published.
As this review is based on projects which have
reached the clinic, it is best seen as a documentation
and discussion of projects which have reached that
stage. This review does not present the status of current
pre-clinical malaria vaccine development, other than
some discussion on links between pre-clinical and clini-
cal results for the projects outlined below.
Status of malaria control
Between 2000 and 2009 there have been major gains in
malaria control in many malaria-endemic countries,
including many in Africa [2]. Total estimated numbers
of deaths related to malaria have dropped from about 1
million in 2000 to about 780,000 in 2009. The numbers
of clinical cases are estimated at 225 million globally by
WHO [3]. These gains are associated with scaling-up of
existing WHO recommended malaria control measures,
including long-lasting insecticidal nets (LLIN), indoor
residual spraying programmes (IRS) and access to arte-
misinin combination therapy(ACT)[3]. There has also
been a shift towards use of rapid diagnostic tests and
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away from presumptive treatment of malaria. Success of
malaria control is vulnerable to the emergence of resis-
tance to artemisinins and insecticides and depends on
the vital imperative for sustained malaria control fund-
ing. Of the five species of Plasmodium that are known
to cause disease in humans, two have received attention
for vaccine development. Over 90% of malaria-related
deaths are caused by Plasmodium falciparum, and there
is a similar dominance for P. falciparum projects in the
malaria vaccine landscape. A single Plasmodium vivax
project is currently in the clinic; this is listed at the end
of the review.
Rationale and goals for malaria vaccine development
Many lines of evidence indicate that humans can be vac-
cinated against malaria. Individuals born in endemic
areas who survive the first years of exposure continue to
develop parasitaemia on natural exposure, but become
resistant first to severe, life-threatening malaria and then
to clinical disease. Frequent re-exposure is required to
maintain this condition of immunity with infection
(concomitant immunity). Transfer of gamma-globulin
fractions from semi-immune to naïve humans mitigates
malaria disease [4,5], demonstrating that clinical protec-
tion from malaria is possible, and that immunoglobulin
targeting malaria antigens can play a critical role. Inocu-
lation of humans with irradiated sporozoites by mos-
quito bite can prevent the emergence of blood-stage
infection after subsequent experimental challenge [6,7],
demonstrating the possibility of inducing high level pro-
tection against infection under experimental conditions.
In endemic areas with natural exposure, sterile immu-
nity rarely if ever develops. Perhaps most importantly
and significantly, the candidate vaccine RTS,S/AS can
induce clinical efficacy in the 25-60% range in different
malaria endemic settings. Thus, the question of feasibil-
ity of malaria vaccination has progressed to an assess-
ment of the public health role of RTS,S vaccination and
the possibility of developing even more efficacious sec-
ond-generation vaccines.
The Malaria Vaccine Technology Roadmap launched
in 2006 expressed intermediate and aspirational commu-
nity goals for vaccine benefits. First, a vaccine with 50%
efficacy against severe disease and malaria-related mor-
tality protecting for more than 12 months, and secondly
a longer-lasting vaccine with 80% efficacy against clinical
malaria [8]. The primary refinement introduced by the
malaria eradication R&D agenda setting process during
2009-2010 is the confirmation that for elimination and
global eradication, impact on transmission rather than
morbidity is the paramount efficacy outcome. There is
general agreement that malaria eradication is not possi-
ble with the currently available tools. Development of a
highly efficacious malaria vaccine which dramatically
reduces transmission would be a transformative tool
that could enable future eradication.
Overview of current status of malaria vaccine clinical
development
Funding has increased substantially over the last 10
years with contributions from agencies such as the Bill
and Melinda Gates Foundation (particularly through
PATH Malaria Vaccine Initiative), the US National
Institute for Allergy and Infectious Disease, European
Union DG RTD, United States Agency for International
Development, Wellcome Trust, Medical Research Coun-
cil UK, the European Vaccine Initiative (formerly
EMVI), European and Developing Countries Clinical
Trials Partnership and WHO [9]. There was a lag of
several years before the funding led to a large increase
in the numbers of clinical trials.
Pre-erythrocytic malaria vaccines designed to produce
sterile protection can be terminated at the challenge
trial stage if no efficacy is demonstrated, whereas blood
stage vaccines generally progress to field evaluation for
proof of concept of clinical effect; thus the timelines to
reach proof of concept for blood-stage vaccines have
been much longer than for pre-erythrocytic vaccines.
This may explain why there are more potential blood-
stage vaccines than other life-cycle stages in clinical eva-
luation, while many pre-erythrocytic concepts have been
tested to failure and terminated, and others are in the
pipeline. Substantial investment in field trial sites for
blood-stage (and pre-erythrocytic) vaccine evaluation
took many years, but is now bearing fruit. Because of
the high cost of large-scale clinical trials, major efforts
continue to find surrogate predictors of efficacy, such as
reduction in incidence of infection, that could be used
to prioritize candidates for the long and expensive clini-
cal field trials. Others are reassessing the evaluation
paradigm for blood-stage vaccines and considering use
of the challenge trial model, together with functional
assays as markers for the down-selection step. Sexual
stage and mosquito antigen vaccines are receiving
renewed attention but are still grossly under-represented
in clinical project portfolios.
Plasmodium falciparum is a highly immuno-evasive,
multi-stage protozoal parasite with several antigenically
distinct mosquito vector and human stages. Molecular
understanding of naturally acquired immunity remains
in its early stages and there are few well characterized
molecular targets that could be selected with confidence
by vaccine developers as being the basis for subunit-
based protection. Thus it is no surprise that many of
the necessarily empiric projects outlined below have not
yielded clinical efficacy [10]. Despite the success of the
P. falciparum, A. gambiae and human genome projects,
there has been little translation of antigenic targets from
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post-genomic antigen discovery to clinical evaluation,
partly because of the problems of selecting appropriate
targets, and the lack of robust and reliable predictive
animal models. What is perhaps more surprising, given
the daunting nature of the task, is that malaria vaccine
developers have produced startling progress in several
areas.
The first human anti-parasite vaccine will be consid-
ered for licensure by regulators in the next few years, as
RTS,S/AS01E progresses through clinical evaluation in a
pivotal Phase 3 trial. This product was developed
through a partnership between GSK and PATH Malaria
Vaccine Initiative, with funds from the Gates Founda-
tion to MVI. Multiple other projects have yielded a
degree of efficacy, notably prime-boost pre-erythrocytic
projects, and very significant expertise and infrastructure
has been developed in African field trial sites. The
recent reductions in malaria transmission in Africa, if
sustained, will render field efficacy trials more difficult
in many current research settings. For some funders,
this drop in transmission together with the partial suc-
cess of RTS,S has shifted emphasis away from blood-
stage vaccines towards pre-erythrocytic and sexual
stage/mosquito (SSM) antigen vaccine development,
emphasising the role they could play in further reduc-
tion of transmission. Clinical evaluation of SSM vaccines
will however be challenging because these vaccines con-
fer efficacy to humans only at the population level and
thus traditional individually randomized trial designs
will not apply without major modification [11,12]. An
additional problem is the lack of knowledge of the rela-
tionship between the effect of a vaccine at an individual
level, such as rendering an individual 80% less infectious
to mosquitoes, and the effect on transmission. For
example, the effect on transmission of a vaccine that
makes x% of people y% less infectious is not known,
although some insights can be gained from modelling.
Success with the novel adjuvants used with RTS,S is
now coupled with an interest in various conjugation or
particulate technologies in attempts to overcome the
poor immunogenicity of soluble monomeric recombinant
malaria proteins [13]. Identification of scalable manufac-
turing processes remains challenging and laborious for
many P. falciparum antigens that have complex multiply
disulphide bonded structures and conformationally
dependent induction of protective IgG. The success of
malaria control also raises the bar for the expected per-
formance of a malaria vaccine. Finally an increased
emphasis on P. vivax R&D has been announced by some
funders, and this has already led to evaluation of one new
P. vivax candidate in Phase 1 [14].
All but one of the projects detailed below is based on
a P. falciparum antigen. It is likely there will be more
emphasis on P. vivax in future as this species becomes
relatively more important from the public health per-
spective. As many of the projects involve multiple part-
ners and funders we have chosen not to provide details
of the vaccine development partnerships here, to avoid
providing incomplete information. These can easily be
found through the references, the clinical trial registry
sites and on the WHO malaria vaccine rainbow table
[1].
The classification of projects below is by species, with
P. falciparum projects first, and by life-cycle stage. For
each life-cycle stage we report currently active projects
first, followed by discontinued/inactive projects. It is
important to note that many of the discontinued/inac-
tive projects have contributed greatly to understandings
of vaccine science [10], and that some will return to the
clinic either in new iterations or without substantial
changes if further funding is obtained. There is a sepa-
rate section for combination vaccines including multiple
life-cycle stages. Combination or polyvalent/multi-epi-
tope constructs focusing on one life-cycle stage are
highlighted as such within the text.
Plasmodium falciparum pre-erythrocytic projects
There is no consensus that pre-erythrocytic immune
responses gained through natural exposure, whether
antibody or cell-mediated immunity (CMI), contribute
substantially to naturally acquired immunity [15], but
the irradiated sporozoite model proves that humans can
be protected by immune responses to sporozoite and
liver-stage parasites. In this sense, sterile immunity con-
ferred by pre-erythrocytic subunit vaccines or attenuated
whole organisms would not be mimicking naturally
acquired immunity, yet this induced “non-natural”
immunity could be more effective than is seen in nature,
whether it supplements or replaces that usually seen in
an endemic area. Candidate vaccine antigens from the
pre-erythrocytic stages may be the targets of antibodies
that prevent sporozoite invasion of hepatocytes or the
targets of cellular immune responses that kill infected
hepatocytes. A completely effective pre-erythrocytic vac-
cine would inactivate the parasite before it left the liver,
leading to sterile immunity and prevention of disease.
This goal may or may not be achievable with the vac-
cines that are currently being evaluated, but a partially
effective vaccine could decrease the incidence of new
infections, and decrease the number of merozoites exit-
ing the liver, by decreasing the number of sporozoites
entering the liver or killing parasites within hepatocytes,
leading to clinical benefits analogous to the direct effects
of insecticide treated bed nets. Partially effective pre-ery-
throcytic vaccines could lead to reductions in both the
size and frequency of blood-stage inocula, which could
result in reductions in mild disease, severe disease and
mortality. A reduced size of inoculum that lengthens the
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gap between infection and patency may allow time for
boosting other immune responses that contribute to
clinical immunity. Reduction in multiplicity of infection
would be another predicted and potentially important
effect of such partially effective vaccines.
CS protein
The Plasmodium circumsporozoite protein (CS) is
expressed during the sporozoite and early liver stages of
parasitic infection [16]. This protein is involved in the
adhesion of the sporozoite to the hepatocyte and inva-
sion of the hepatocyte. Anti-CS antibodies have been
shown to inhibit parasite invasion and are also asso-
ciated with a reduced risk of clinical malaria [17,18] in
some studies, though the relative importance of anti-CS
responses in naturally acquired immunity remains con-
troversial. Antibodies raised through immunization with
only the conserved Asparagine-Alanine-Asparagine-Pro-
line (NANP) amino acid repeat sequence, the immuno-
dominant B-cell epitope from P. falciparum CS, are
capable of blocking sporozoite invasion of hepatocytes
[19]. The demonstrated protective role of vaccine-
induced anti-CS responses and the fact that CS is the
predominant surface antigen of sporozoites [19], have
made CS the most popular antigen for use in pre-ery-
throcytic vaccine candidates. In this regard it is set apart
from other candidate vaccine antigens, as the lead anti-
gen. Evidence for antigen specific vaccine-induced effi-
cacy against morbidity is far stronger for CS than any
other antigen.
RTS,S/AS01E
Clinical development of RTS,S/AS01E has been reviewed
extensively [20-22]. This is by far the most advanced
candidate malaria vaccine, is the only one in Phase 3
evaluation, and is at least 5-10 years ahead of all other
projects. RTS,S/AS01E has demonstrated 51% efficacy
(95%CI 29-66) in reducing the rate of all episodes of
clinical malaria over fifteen months of follow-up in a
Phase 2 trial in children aged 5-17 months resident in
Kilifi, Kenya [23]. Immunologic analyses indicate that
high titre anti-CS IgG are most strongly associated with
RTS,S-mediated protection, with an important additive
component from CS-specific Th1 cells. One recent
study highlighted a correlation between CS-specific
TNFa(+) CD4 (+) T cells and reduced morbidity, which
requires confirmation in other studies [24]. The ongoing
Pivotal Phase 3 trial started in May 2009 and has
enrolled 15,460 children over 6,000 of whom are in the
6-14 week EPI co-administration age group. The full
trial results are expected in 2014 and will include the
following information: safety and reactogenicity of a vac-
cine containing a novel adjuvant, co-administration data
with pentavalent DTwP/HepB/Hib and OPV, efficacy in
multiple transmission settings, efficacy data over 30
months of follow-up, an 18 month booster dose and
efficacy against severe, life-threatening malaria. The first
of 3 sets of results from the Phase 3 trial was published
on 18 Oct 2011 and was in line with expectations from
the Phase 2 trials [25,26]. The trial, conducted at 11
trial sites in seven countries across sub-Saharan Africa,
reported that RTS,S reduced the incidence of all epi-
sodes of clinical malaria by 55% (95%CI 51-59) when
evaluated over 12 months following the third dose. This
analysis was performed on data from the first 6,000 chil-
dren aged 5 to 17 months. A primary analysis for severe
malaria efficacy was planned when 250 cases accrued in
both the 5-17 month and 6-14 week age groups of the
trial. This analysis reported an efficacy of 35% (95%CI
16-49) with variable follow-up from zero to 22 months
after the third dose. There are many lessons to be
learned from the RTS,S trials including the major con-
tribution of sporozoite challenge trials, the importance
of adjuvant, dose and schedule optimization, and the
need to use particulate structures to enhance
immunogenicity.
There is a standing WHO advisory group, known as
the Joint Technical Expert Group, which will review
data as they become available from the Phase 3 trial.
Policy recommendation timings are data-driven.
Depending on the full trial results expected in 2014,
WHO recommendation for use may occur in 2015.
Adenovirus (Ad35) vectored CS
RTS,S/AS01E induced very potent anti-CS Ig responses,
modest CD4+ g-interferon T cell responses and low or
absent CD8 responses. The approach considered most
likely to improve upon CS-mediated protection would
be to employ a prime-boost combination of RTS,S/AS01
with a CD8-inducing CS vaccine. The non-replicating
adenovirus 35 vector encodes the CS protein. In precli-
nical development the vaccine induced strong IFN-g
responses in mice including CD8+ responses, thought to
be important for protective immunity in humans
[27,28]. Phase 1 human studies examining safety and
immunogenicity have occurred at Stanford and Vander-
bilt Universities [29] with a Phase 1b study in Burkina
Faso now completed [30]. The potential interference of
antibodies induced by previous natural exposure to Ad
5 is not known, but one attraction for adenovirus 35 is
the much lower seroprevalence of antibodies to this
virus than adenovirus 5 [31]. The HIV STEP trial results
[32] are thought by some to represent a roadblock to
the future of adenovirus 5 as a vector for prophylactic
vaccine.
Ad35 vectored CS in prime-boost with RTS,S/AS01E
Crucell announced in 2009 that they have agreed to
work with GSK to evaluate adenovirus 35 CS/RTS,S
prime-boost combinations, hopefully reproducing the
promising non-human primate results seen with this
approach [33]. Regimens based on RTS,S/AS01, but
Schwartz et al. Malaria Journal 2012, 11:11
http://www.malariajournal.com/content/11/1/11
Page 4 of 22
including rational prime-boost additions or additional
antigens in combination, are the most likely near-term
possibilities for improving efficacy induced by RTS,S/
AS01 alone. The Phase 1/2a sporozoite challenge study
began in August 2011 comparing one dose of Ad35 CS
followed by two doses of RTS,S/AS01 with 3 doses of
RTS,S/AS01 alone [34].
Multiple epitope constructs
Some vaccine strategies use components of multiple
pre-erythrocytic antigens in one vaccine to elicit a broad
immune response intended to prevent blood-stage infec-
tion. This approach is intermediate between traditional
single antigen constructs and combinations of whole
antigens. One example is the ME-TRAP construct, a
pre-erythrocytic fusion antigen consisting of 17 B cell,
CD4+ and CD8+ T cell epitopes from six P. falciparum
antigens fused to the T9/96 allele of TRAP (thrombos-
pondin-related adhesion protein) pre-erythrocytic anti-
gen. It includes a single Plasmodium berghei CD8+ T
cell epitope (Pb9) for potency studies in mice. The vac-
cine construct is based on the attractive concept of IFN-
g mediated elimination of infected hepatocytes [35,36].
TRAP is another protein expressed both on the surface
of sporozoites [37] and within infected hepatocytes [38].
AdCh63/MVA ME-TRAP
During preclinical development of this vaccine, a prime-
boost sequence of simian adenovirus (AdCh63) encod-
ing for ME-TRAP boosted with modified vaccinia virus
Ankara (MVA) encoding the same construct elicited
exceptionally strong and long-lasting CD8+ T cell
responses [36,39]. Initial studies had used human adeno-
viruses, but previous exposure to the vector could pro-
duce neutralizing antibodies that would interfere with
immunogenicity. This problem is overcome through use
of simian adenovectors to which humans do not have
cross-reactive antibodies. In the UK a Phase 1 study and
a Phase 2 sporozoite challenge study should be com-
pleted during 2011 [40,41]. The first adult Phase1 Ken-
yan study had started by November 2010 and a Phase
1b field trial in the Gambia has also occurred [1].
Prime-boost approaches including adenoviruses appear
particularly promising for achievement of the long
desired outcome of strong induction of CD8 T cell
responses in humans; the strain of adenovirus used may
be vital to the immunogenicity and efficacy afforded,
both in malaria-naïve individuals and in malaria-ende-
mic settings.
Polyepitope DNA EP1300
This pre-erythrocytic DNA vaccine includes multiple
epitopes with linker sequences from four pre-erythrocy-
tic antigens, CS, SSP2/TRAP, Liver-stage antigen 1
(LSA-1) and Exported protein 1 (Exp-1) and is adminis-
tered via electroporation. The strategy is being assessed
in Phase 1a studies in naïve volunteers in the US which
started during 2010 [42]. Few further details are avail-
able. The immunogenicity of DNA vaccines in animal
models has generally not been reproduced in humans.
Augmentation has previously been attempted with var-
ious intradermal, subcutaneous and intramuscular deliv-
ery devices [43]. Electroporation has augmented
immune responses impressively in some animal models
[44,45] and in a Phase 1 clinical trial of an HIV vaccine
construct [46]. It remains to be seen whether tolerability
will be acceptable and immunogenicity sufficient for
prophylactic paediatric vaccination in humans. This pro-
ject also touches on the important question of how to
best ensure immunogenicity of multiple epitopes or
antigens in DNA-based approaches.
Whole organism approaches
PfSPZ: metabolically active, non-replicating malaria
sporozoite vaccine
Using the knowledge that volunteers can be protected
from sporozoite challenge by immunization via bites
from > 1,000 irradiated P. falciparum-infected mosqui-
toes, a biotech company has developed an approach
using injection of metabolically active, non-replicating
whole P. falciparum sporozoites thawed from long-term
storage in liquid nitrogen. The vaccine should confer
sterilizing immunity in principle, but challenges arise
from manufacturing and scaling up of the product,
dosage and administration methods, and the logistics of
delivering a vaccine that is cryopreserved in liquid nitro-
gen [47-49]. In initial Phase 1/2a studies to examine the
safety and immunogenicity of different dosages and i.d.
and s.c. routes of administration in malaria naïve volun-
teers [50], two out of 44 subjects challenged were com-
pletely protected, but refinements to the dose, route or
schedule or improvements in adjuvants are required for
a vaccine likely to have significant impact on morbidity.
With such a novel vaccine technology, it is likely that
several further Phase 1 trials will be necessary to identify
a regimen that can replicate the results previously seen
when irradiated sporozoites were delivered by mosquito
bite. A follow-on Phase 1/2a of i.v. administration is
underway [51].
Genetically attenuated sporozoites
Another whole organism approach is inoculation of
genetically attenuated parasites. A multi-institutional
partnership is developing and testing genetically attenu-
ated sporozoites as whole organism pre-erythrocytic
immunogens [52,53]. A Phase 1 study has occurred; no
report had been made at the time of writing.
Discontinued/inactive pre-erythrocytic projects
FP9 CS/MVA CS
This strategy assessed whether priming with an attenu-
ated fowlpox strain (FP9) expressing the pre-erythrocytic
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CS protein and boosting with MVA also coding for the
CS protein would elicit strong cellular responses. A
Phase 1/2a study in malaria naïve subjects in the UK
found that while the vaccine regimen was safe, the T
cell response was modest and MVA did not boost this
T cell response convincingly. When challenged with
sporozoites, there was no protection of study subjects
and no partial protection, defined by a delay in time to
parasitaemia [54]. Conversely, in a Phase 1b study in
Gambian adults, IFN-g producing CD4+ and CD8+ cells
were substantially elevated after boosting with MVA
with the most likely explanation being priming of the
response by natural infection [55]. Interestingly this
result was predicted by earlier pre-clinical research on
natural priming performed by a group at New York
University [56].
DNA CS/MVA CS
This prime-boost regimen replaced FP9 above with a
plasmid DNA encoding the CS protein as a priming
agent. In a Phase 1/2a study in the UK, the T cell
response was again modest and there was no difference
in time to parasitaemia between those vaccinated and
the controls after sporozoite challenge [57]. Thus
whether DNA/poxvirus or heterologous viral/viral
prime-boost approaches are used, the ME-TRAP con-
struct seems to be substantially more immunogenic
than the CS construct. This is an important lesson for
future projects; one reason for failure of a given prime-
boost regimen may be an insufficiently immunogenic
antigen and should not necessarily be ascribed to the
choice of priming and boosting platforms alone.
RTS,S/AS02 + MVA CS
This vaccine regimen was assessed in order to deter-
mine if boosting RTS,S/AS02 with MVA encoding the
P. falciparum CS protein would elicit equivalent anti-
body titres but greater CMI response than RTS,S/AS02
alone. A Phase 1/2a study in malaria naïve adults in the
UK found the prime-boost combination to be safe, but
elicited little or no incremental benefit for this regimen
compared with RTS,S alone. After sporozoite challenge,
vaccine efficacy for complete protection was 2/6 volun-
teers, the same order of magnitude as protection seen
with RTS,S/AS02 alone in previous studies. As with
RTS,S/AS02 alone, some volunteers showed a delay in
parasitaemia. Disappointingly, MVA-CS did not aug-
ment the CS-specific CMI response to RTS,S/AS02 [58].
The objective of this study remains highly relevant as
the community searches for alternative viral vectors
which could augment the CD8 CMI response to RTS,S.
CS DNA immunization
In this strategy, the gene for full length CS protein was
inserted into naked plasmid DNA. Multiple Phase 1a
studies assessed the safety and immunogenicity of this
vaccine, also named VCL-2510, using intramuscular,
intradermal and needle-free delivery to induce humoral
and cellular responses. While all routes of delivery were
safe and elicited some CD8+ T cell responses, no anti-
CS antibodies were detected [59-61]. These early studies
demonstrated that DNA vaccines alone were substan-
tially less immunogenic in humans than had been
observed in small animal models.
MuStDO5 (Multi-Stage DNA vaccine Operation, 5 antigens)
This is a combination of DNA plasmids that encode CS,
SSP2/TRAP, Exp1, LSA1 and LSA3 adjuvanted with
GM-CSF (Granulocyte Macrophage Colony Stimulating
Factor). There was no efficacy detected in the challenge
study [62] and the investigators have now moved away
from DNA plasmid immunization alone.
DNA CS/RTS,S/AS02
The DNA vaccine VCL-2510 containing the full length
CS gene had been shown to elicit some CD8+ T cell
responses and RTS,S/AS02A had elicited CD4+ T cell
and anti-CS IgG responses. Vaccination with VCL-2510
followed by boosting with RTS,S/AS02 12-14 months
later was safe and immunogenic. The anti-CS antibody
and CD4+ response among those boosted was not sig-
nificantly different from those vaccinated with RTS,S
alone, but the DNA/protein prime-boost regimen
induced memory CD8+ T cell responses not seen
among those vaccinated with only RTS,S [63,64]. How-
ever CD8+ T cell g-interferon responses were not
induced as measured by ELISPOT assays conducted on
freshly isolated cells.
RTS,S/AS02 and TRAP
There is currently no published literature available on
this project, but a Phase 2a challenge trial with this vac-
cine has taken place [1]. It is very important to under-
stand the study design and the outcomes of the project,
because combination of CS and TRAP recombinant pro-
tein vaccines is a highly logical approach to improving
upon RTS,S-mediated efficacy to date. It will be impor-
tant to determine whether this approach has been ade-
quately tested to failure, or whether further trials are
justified with improved TRAP-based recombinant pro-
tein constructs.
HepB Core-Ag CS VLP
Several clinical studies have assessed this vaccine, also
called ICC-1132 or Malarivax, a virus like particle with
hepatitis B core antigen genetically engineered to
include one B cell epitope and 2 CD4+ T cell epitopes
of the CS protein and expressed in E. coli. Phase 1 stu-
dies of the vaccine adjuvanted in alhydrogel showed
acceptable safety with anti-ICC-1132 antibody and IFN-
g induction, but limited malaria specific anti-CS antibo-
dies [65]. Reactivity in functional assays was present in a
proportion of vaccinees [66]. When the vaccine was
adjuvanted with Montanide ISA 720 and given as a sin-
gle dose, volunteers seroconverted for IgG to CS but at
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lower titres than have occurred after 2-3 doses of RTS,S
adjuvanted with AS01, 02 or 03 [67]. Although 2 or 3
dose regimens may have been more immunogenic, a
single dose ISA 720 regimen was chosen for evaluation
in a challenge trial because sterile abscess formation had
been seen in non-human primates after 2 doses of ICC-
1132 in ISA 720. The challenge trial showed no efficacy
against sporozoite challenge [68]. Not long after this
study ICC-1132 development was discontinued.
CS long synthetic peptide
PfCS102 is a chemically synthesized segment of the P.
falciparum CS protein containing the C-terminal region
with amino acids 282-383. Several Phase 1 studies
examined this vaccine construct at varying dosages and
combined with different adjuvants. The first Phase 1a
study examined PfCS102 adjuvanted with Montanide
ISA 720 and alum. Overall, both vaccines were safe and
elicited lymphocyte proliferation in all subjects. The ISA
720 adjuvanted vaccine elicited higher antibody levels
and enhanced functional activity. Cellular responses
were short lived [69]. A second Phase 1a studied exam-
ined the vaccine adjuvanted with ISA 720 and GSK’s
AS02A. In this study AS02A induced stronger humoral
and cellular responses [70]. During the 1/2a challenge
study, conducted with Montanide ISA 720 alone, all
volunteers including controls and vaccinees developed
malaria with no difference in time to parasitaemia [71].
There is much debate about the importance of using
full length CS, and several groups are now exploring
pre-clinical development of full length CS constructs.
FP9/MVA & DNA/MVA ME-TRAP
In order to identify the safest and most immunogenic
prime-boost regimen to elicit cellular immunity to the
liver stage antigen ME-TRAP, multiple non-replicating
viral vectors were compared in Phase 1/2a clinical stu-
dies in the UK and several field studies in malaria ende-
mic regions [72]. The current clinical programme is
focusing on AdCh63 priming and MVA boosting, a regi-
men confirmed to be highly immunogenic. Prior to this
selection, attenuated fowlpox (FP9) or plasmid DNA for
priming, followed by MVA boosting had been assessed.
Both prime-boost regimens were safe and elicited strong
cell-mediated IFN-g responses, with DNA/MVA ME-
TRAP eliciting a stronger response in CD4+ T cells and
FP9/MVA ME-TRAP stimulating more CD8+ T cells
[73,74], though much weaker CD8 induction than seen
with AdCh63/MVA. After a challenge study in malaria
naïve adults showed complete protection in some volun-
teers, Phase 1b studies in Kenyan adults and children
assessed the safety and immunogenicity of FP9/MVA
ME-TRAP [75,76]. These trials also demonstrated strong
IFN-g responses via ex vivo and cultured ELISPOT [77].
A Phase 2 study in Kenyan children resulted in a lower
than anticipated T cell response and the vaccine
afforded no protection against febrile malaria [78,79].
Earlier trials examining the DNA/MVA ME-TRAP
prime-boost vaccination schedule in adults from the UK
demonstrated an increase in CD4+ and CD8+ IFN-g
producing cells and a delay in time to parasitaemia
compared with homologous vaccination [80]. While
field trials in the Gambia of the same vaccine regimen
confirmed good T cell immunogenicity, the efficacy in
terms of time to first infection was only 10.3% (95%CI
-22-34) [81]. These trials also confirmed that priming by
naturally acquired infection could be boosted by recom-
binant poxviruses [82].
FP9/MVA polyprotein
This prime-boost strategy combined the non-replicating
viral vectors FP9 and MVA. The very long (3,240 amino
acid) polyprotein encoded by the vectors consisted of 6
antigens; liver stage antigen-3 (LSA3), sporozoite threo-
nine and asparagine rich protein (STARP), Exp1, Pfs16,
TRAP, and LSA1. During the preclinical Phase, the vac-
cines elicited promising T cell responses to each of the
six antigens in certain inbred mouse strains [83], but
clinical development ceased due to low efficacy in spor-
ozoite challenge [84]. This was disappointing, because
the capacity of poxviruses to encode very large inserts,
could be a way to include multiple antigens, if single
antigen approaches prove inadequate. It may be that
optimization of expression, for example with multiple
promoters, could improve upon the results seen with
this construct.
FMP011/AS01B (LSA-1 E. coli-expressed evaluated with
AS02A and AS01B adjuvants)
LSA-1 is a pre-erythrocytic antigen expressed only in
infected hepatocytes and LSA-1 antibodies have been
associated with reduced risk of malaria blood-stage
infection [85]. This candidate used LSA-NRC, an anti-
gen containing T cell epitopes of the N and C terminal
regions of LSA-1 and several central amino acid repeats.
The antigen was expressed in E. coli and used with GSK
adjuvants AS01B or AS02A. In a Phase 1/2a trial the
vaccines showed acceptable safety among malaria naïve
adults, with high titre anti-LSA-1 antibodies. Unsurpris-
ingly for a regimen using a recombinant protein plat-
form, CD8+ T cells were low or undetectable among
both groups. Volunteers who received a high dose of
either vaccine were challenged, but none were protected
and there was no delay in parasitaemia [86].
LSA-3
A liver-stage antigen 3 (LSA-3) L. lactis expressed
recombinant protein has been evaluated in the clinic,
adjuvanted with either aluminum hydroxide or Monta-
nide ISA 720 [87]. During a Phase 1/2a study conducted
in 2008, one volunteer developed an acute coronary syn-
drome in temporal association with malaria sporozoite
challenge. The coronary syndrome resolved [88] and has
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led to consensus in the malaria challenge community
that formal algorithmic exclusion of those at high cor-
onary risk is appropriate as a precautionary measure in
all malaria challenge trials [89]. The safety, immuno-
genicity and efficacy results of the LSA-3 trial have not
yet been published to our knowledge. Proof-of-concept
testing for LSA3 remains uncompleted for the time
being.
Plasmodium falciparum blood stage projects
Transfer of immunoglobulin from immune adults to
children suffering acute malaria mitigates clinical disease
[4,5], but it is not clear whether the targets of naturally
acquired protection to severe disease, uncomplicated
disease and blood stage infection overlap at a molecular
level. Most studies examining incident infection have
used parasite detection by microscopy as the endpoint,
but it is clear that subpatent infections occur not
uncommonly in partially immune people. Thus some
studies describing “sterile immunity” may in fact be
measuring very effective blood stage immunity that is
not sterilizing but maintains parasitaemia at subpatent
levels. As discussed earlier, there is little consensus on
the degree of contribution of the pre-erythrocytic stages
to naturally acquired immunity, but what is clear is that
adults with substantial anti-disease immunity become
reinfected rapidly on exposure to sporozoites in endemic
countries. Furthermore, historical reports of blood-stage
challenges of immune adults showed attenuated infec-
tions with immunity targeting the blood stages alone
[90]. Antigenic polymorphism is a major challenge for
most blood stage antigenic targets.
MSP-1
Merozoite Surface Protein 1 (MSP-1) is expressed from
the onset of schizogony and is involved in erythrocyte
invasion by merozoites. Much is known about the struc-
ture and function of MSP1 and the possible immune
effector mechanisms of MSP1-specific immunity [91].
Anti-MSP-1 antibodies have also been associated with
decreased risk of clinical malaria, in an allele-specific
manner [92]. The weight of evidence is that IgG induc-
tion is more important for MSP1 than cell mediated
effector responses.
AdCh63/MVA MSP1
This prime-boost strategy utilizes the simian adenovirus
63 vector boosted by MVA, both expressing portions of
the P. falciparum MSP1 protein, including the
dimorphic forms (3D7 and FVO) of the 33kd C-terminal
segment as well as MSP1(19) and parts of the N-termi-
nus. Because MSP1 is a very large protein, all clinical
projects to date have attempted to identify critical seg-
ments of the whole protein for inclusion in the vaccine
construct. A Phase 1 trial reported very high mixed
CD4/CD8 T cell induction with some IgG induction in
addition [93]. A Phase 2a study has also occurred
[94,95].
FMP010/AS01B
FMP010 is an E. coli expressed FVO allele of the 42kD
C-terminus of MSP1 and is adjuvanted with the GSK
product AS01B. A Phase 1 study examining safety and
immunogenicity via growth inhibition assays has
occurred [96]. Phase 1b studies were underway in semi-
immune populations in Kenya in 2010 [1]. This project
follows the previous studies of FMP001/AS02A, a vac-
cine based on the 3D7 allele of MSP1, and showing
good immunogenicity but inadequate clinical efficacy in
a Phase 2b trial [97], possibly because multiple vaccine
alleles would be necessary to generate a sufficiently
broad strain-transcending immune response.
MSP-3
Merozoite Surface Protein 3 (MSP-3) is unique in that
its anti-parasitic activity was discovered through the
exploration of the phenomenon that passive transfer of
IgG to naïve volunteers mitigated disease and was asso-
ciated with reduced disease via antibody dependent cell
mediated inhibition (ADCI). Search for the targets of
ADCI identified the highly conserved MSP3 antigen and
the resulting cytophilic IgG1 and IgG3 anti-MSP3 anti-
bodies as sources of parasitic growth inhibition [98]. A
systematic review of immuno-epidemiological studies
reported that MSP3 was the blood-stage antigen with
the most consistent associations between antibody
responses and reduced risk of clinical malaria, in multi-
ple settings [92]. A Phase 1a study in healthy Swiss
volunteers demonstrated that the long synthetic peptide
MSP3 vaccine elicited a strong humoral response with
low reactogenicity when used with aluminum hydroxide
adjuvant [99]. Conversely, a Phase 1b trial of semi-
immune adults in Burkina Faso resulted in little
humoral and modest cell-mediated responses to the vac-
cine, most likely due to previous exposure and elevated
baseline anti-MSP3 antibodies [100,101]. Two Phase 1b
trials at sites in Tanzania and Burkina Faso in children
aged 12-24 months reported tolerable reactogenicity and
good IgG1 and IgG3 cytophilic humoral responses
[102,103]. Over 80% of children in both dose groups
had a greater than 8-fold increase in IgG subclass titre
in the Tanzanian study. Further Phase 1-2 studies in
Mali and Burkina Faso have commenced and should be
completed during 2011. The reporting of a paediatric
Phase 2b study in Mali is awaited [104]. An exploratory
analysis of the Phase 1b trial from Burkina Faso of
MSP-3 long synthetic peptide adsorbed on aluminium
hydroxide reported that rates of clinical malaria in chil-
dren who received the vaccine in 2 dose groups were
lower than in the control group who received hepatitis
B vaccine [105]. The sample size was small, and whilst
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interesting, this finding requires confirmation in a pro-
spective Phase 2 field efficacy study.
AMA-1
Apical Membrane Antigen 1 (AMA1) is a blood-stage
antigen that aids in orienting the merozoite during inva-
sion of erythrocytes and is also expressed during the
sporozoite and hepatic stages. Studies have also shown
that anti-AMA1 antibodies tend to be present in those
who have acquired natural immunity to malaria
[106,107] and repeated natural exposure often leads to
high titres of IgG to AMA1. This is in contrast to CS
for which even intense exposure induces quite low titres
of antibody. The extreme polymorphism of this candi-
date vaccine antigen suggests that the human immune
system exerts a strong selective pressure [108]. These
both provides rationale for use of AMA1 as a vaccine in
that it is subject to immune pressure, but implies that
novel approaches, able to induce strain-transcending
responses, will be necessary for useful efficacy.
FMP2.1/AS02A
A Phase 1a study with malaria naïve volunteers examin-
ing the effect of vaccination with FMP2.1, in which E.
coli expressed AMA1 (3D7 strain) is adjuvanted with
the GSK product AS02A, showed acceptable safety and
induction of strong humoral and cell-mediated
responses [109]. In a Phase 1b study in Malian adults
the vaccine was safe, induced a strong antibody
response, but displayed a strongly Th-2 biased cell-
mediated immunogenicity [110,111] in contrast to a
more balanced Th1/Th2 profile in vaccinated malaria-
naïve adults. A Phase 1b dose-escalating study of the
same vaccine in Malian children induced at least 100-
fold rise in antibody titres compared with baseline anti-
AMA1 antibodies, at all three doses [112]. A Phase 2
study in 400 Malian children aged 1-6 reported no sig-
nificant efficacy against the primary clinical malaria end-
point, but was consistent with allele-specific efficacy
against the AMA1 allele contained in the vaccine [113].
FMP2.1/AS01B
The FMP2.1/AS01B vaccine candidate uses the same
antigen (E. coli expressed AMA1 (3D7 strain)) with the
AS01B GSK adjuvant. Both adjuvants contain the same
amounts of 3-D-MPL (3-deacylated-monophosphoryl
lipid A) and QS-21. AS01B is liposome based while
AS02A is an oil-in-water emulsion. A Phase 1/2a study
in malaria naïve volunteers demonstrated high titres of
anti-AMA1 antibody, inhibition of parasite growth in
vitro, and strong IFN-g ELISPOT responses. However,
after sporozoite challenge, all volunteers became parasi-
taemic [114]. There was an indication of reduction of
the liver-to-blood inoculum for both FMP 2.1/AS02A
and FMP2.1/AS01B vaccinees, but the reduction was
marginal as assessed by a mathematical model of the
qPCR data, with no corresponding difference in pre-
patent period as measured by microscopy. There was
one notable adverse event 18 days after the second
FMP2.1/AS01B vaccination, a rash consistent with a
cutaneous immune-mediated hypersensitivity reaction.
The rash intermittently recurred at the site of the two
previous vaccinations over 3 months [114].
AMA-C1/Alhydrogel + CpG 7909
The antigen for this vaccine candidate is Pichia pastoris
expressed AMA1 with both FVO and 3D7 strains of
AMA1. In previous studies with AMA-C1/Alhydrogel,
vaccine trials resulted in low titres of anti-AMA1 anti-
bodies and little response in the functional in vitro
growth inhibitory assay. Thus the vaccine developers
evaluated adjuvant combinations of Alhydrogel +/- CpG
7909, a toll-like receptor 9 agonist favouring a Th1 bias
and a more potent antibody response. There has been a
single case of a serious autoimmune disease known as
Wegener’s granulomatosis in association with a hepatitis
B vaccine adjuvanted with an oligonucleotide similar to
CpG 7909. Therefore special attention was paid to pos-
sible autoimmune disease in these malaria studies. In a
Phase 1a vaccine trial in malaria-naïve adults, addition
of CpG was associated with substantially higher IgG
responses and increased in vitro growth inhibition for
both FVO and 3D7 strains [115]. A Phase 1b study in
Mali comparing the two vaccines also showed a signifi-
cantly higher geometric mean antibody titre in the CpG
arm as compared to the vaccine without CpG. Differ-
ence in the growth inhibition assay activity was not sig-
nificant, but investigators hypothesize this is due to
interference from naturally acquired malaria specific IgG
[116]. A Phase 2 study in 300 Malian children aged 2-3
evaluated AMA-C1 with alhydrogel but without CpG.
There was no detectable beneficial biological impact of
vaccination in terms of reduction in occurrence of para-
site density above pre-defined thresholds [117]. Impor-
tantly there was an apparent reduction in haemoglobin
concentration in AMA1-C1 vaccinees. As this was seen
in 2 of 16 reported secondary endpoints, it should be
treated with caution. However, this is a biologically
plausible outcome of vaccination with an immunogen
based on a blood stage antigen and further analysis is
warranted. An elegant exploration of allele-specific effi-
cacy in this Phase 2 trial has been published with no
indication of an allele-specific effect [118].
AdCh63 AMA1/MVA AMA1
This vaccine strategy uses the simian adenovirus
AdCh63 expressing AMA1 to prime the immune system
and MVA expressing AMA1 to boost. Phase 1a studies
for safety and immunogenicity as well as Phase 2a chal-
lenge trials have commenced [95,119]. There is now
clinical trial data for AdCh63/MVA prime-boost with 3
different antigens. These confirm that this approach is
exceptionally immunogenic for CMI, inducing average
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ELISPOT responses of greater than 1,000 spot-forming
cells per million peripheral blood mononuclear cells,
with CD8 responses being greater than CD4 responses.
It remains to be seen whether the IgG induction will be
sufficient for blood stage antigens.
EBA175 RII
The EBA175 protein is a blood stage antigen that aids
binding of the merozoite to host erythrocytes. The RII
region of the protein is highly conserved among the var-
ious strains of P. falciparum. In a recent Phase 1 study in
adult malaria naïve volunteers, a recombinant protein
made in P. pastoris, adjuvanted with aluminium-phos-
phate, resulted in a safe and immunogenic response at
varying doses [120,121]. Sera from volunteers had anti-
EBA175 RII antibodies that demonstrated modest parasi-
tic growth inhibition and inhibition of parasitic binding
to erythrocytes in vitro. A Phase 1 study in semi-immune
adult volunteers in Ghana was underway in 2010 [122].
SERA5
This blood stage antigen is expressed during the tropho-
zoite and schizont stages. SE36 is an E. coli expressed
recombinant protein corresponding to a fragment of the
SERA5 antigen. Seroepidemiologic studies in the Solo-
mon Islands found anti-SE36 antibodies to be inversely
related to parasite density. In a Phase 1a vaccine trial in
malaria naïve Japanese males, the vaccine candidate had
acceptable safety and resulted in 100% seroconversion
[123]. A Phase 1b trial in semi-immune Ugandan adults
has recently been completed [124].
Combinations of multiple blood stage antigens
MSP1 and AMA1 combination: BSAM-2/Alhydrogel + CPG
BSAM-2 is a combination vaccine including MSP1 and
AMA1 components. It contains a mixture of recombi-
nant proteins with equal parts P. pastoris expressing
FVO and 3D7 strains of AMA1 and E. coli expressing
the FVO and 3D7 strains of MSP1 (42). Each compo-
nent is adjuvanted with alhydrogel and the solution is
mixed with CPG 7909 before vaccination. A Phase 1a
study in naïve adults in the US and a Phase 1b study in
semi-immune Malian adult is currently taking place
[125].
MSP1 19 and EBA175 combination: JAIVAC
This combination vaccine consists of MSP1(19) and
EBA175, each of which is an E. coli expressed recombi-
nant protein adjuvanted with Montanide ISA 720. A
Phase 1a clinical trial has recently started in India [126].
This approach targets two antigens with distinct roles in
merozoite invasion in the hope that the combination
could have additive or synergistic effects over a vaccine
based on one target alone [127].
MSP-3 and GLURP combination: GMZ2
The GMZ2 candidate vaccine is a L. lactis expressed
recombinant fusion protein of Glutamate Rich Protein
(GLURP) and MSP3, adjuvanted with aluminum hydro-
xide. A Phase 1a study of the GMZ2 vaccine in malaria
naïve German volunteers showed acceptable safety and
reactogenicity along with induced anti-GLURP and anti-
MSP3 antibodies and memory B-cells [128]. A Phase 1b
clinical trial in semi-immune adults from Gabon also
showed acceptable safety, a boosted anti-GMZ2 cytophi-
lic IgG response compared with elevated baseline levels,
and the induction of memory B-cells [129]. A Phase 1b
study in Gabonese children was recently reported [130]
with both IgG and memory B cell induction confirmed
for GMZ2. Phase 2b studies have been planned for
Uganda, Burkina Faso, Ghana and Gabon [1].
Discontinued/inactive blood stage projects
RESA, MSP1, MSP2 (Combination B)
The Combination B vaccine consisted of a mixture of
three antigens expressed in E. coli and adjuvanted with
Montanide ISA 720. The antigens included the N-term-
inal blocks 1 and 2 of MSP1 (K1 allele), the full length
3D7 allele of MSP2, and a large C terminal fragment of
the ring-infected erythrocyte surface antigen (RESA). In
a Phase 1/2a study in malaria naïve adults all partici-
pants developed parasitaemia and did not experience
any delay in growth rate as compared to controls
[131,132]. A Phase 1/2b study in children in Papua New
Guinea assessed parasite density as an efficacy endpoint.
Among children who were not pre-treated with sulpha-
doxine/pyrimethamine there was a parasite density
reduction of 62% (95%CI 13-84), but vaccine efficacy
related to prevalence of infection by microscopy, acqui-
sition of new infections and acquisition of clinical
malaria was not detected [133-136]. Molecular analyses
showed that vaccinees had lower prevalence of parasites
carrying a 3D7-type allele and fewer clinical episodes
with this variant (corresponding to that in the vaccine).
The results provided stimulus for the now discontinued
MSP2 bi-allele approach.
FMP1/AS02A
Falciparum Malaria Protein-1(FMP1) contains the 42
kDa carboxyl terminus of Merozoite Surface Protein-1
(MSP1) (3D7). The antigen is expressed in E. coli with a
histidine tag and adjuvanted with AS02A. A Phase 1a
trial in malaria naïve volunteers showed the vaccine to
have acceptable safety and elicited strong humoral and
cellular responses, as well as functional inhibition of
parasite growth [137]. Two Phase 1b studies, in Kenya
and Mali, showed reasonable induction of anti-MSP1
IgG among semi-immune adults with high titres of IgG
at baseline [138,139]. A Phase 1b study in Kenyan chil-
dren confirmed acceptable safety and immunogenicity
with a higher induced titre and lower baseline as
expected [140]. However, the Phase 2b trial in 400 Ken-
yan children aged 12-47 months reported vaccine
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efficacy of 5.1% (95%CI -26-28) with no reduction in
parasite density [97]. The allele-specific efficacy analyses
from this trial are awaited as the absence of a strain
transcending response would be one logical reason for
lack of efficacy.
MSP1-C1/AlOH/AlOH + CpG
MSP1-C1 is a combination of FVO and 3D7 strains of
MSP1(42) as recombinant proteins expressed in E. coli.
Original formulations of the vaccine had MSP1-C1 adju-
vanted with alhydrogel, but Phase 1 studies found this
formulation to be only modestly immunogenic [141]
with little activity in a growth-inhibition assay (GIA). In
a Phase 1a study in malaria naïve subjects, addition of
CpG substantially increased the humoral response to
MSP1 [142,143]. We are not aware of planned further
development of MSP1-C1 alone, but rather as part of
BSAM-2/Alhydrogel + CpG, a MSP1/AMA1 combina-
tion [125]. A separate comparison of GIA for equivalent
IgG concentrations of anti-AMA1 and anti-MSP1 anti-
bodies confirmed that antibodies to AMA1 are far more
potent for growth inhibition in vitro [144].
MSP2-C1/ISA 720
MSP2-C1/ISA 720 is a combination of 3D7 and FC27
strains of MSP2 as recombinant proteins, adjuvanted
with montanide ISA 720. While the vaccine elicited
strong humoral and cellular responses in a Phase 1a
study, the trial ended prematurely due to increased reac-
togenicity at the injection site and issues with vaccine
stability [1]. The impetus for MSP2-C1 was the results
from an earlier trial of Combination B [136], a vaccine
which contained one allele of MSP2 and whose efficacy
analyses suggested a possible MSP2-related allele-speci-
fic effect. It is therefore disappointing that the MSP2-C1
combination was not evaluated in an efficacy study. It
would be beneficial to clarify whether this construct has
been terminated due to funding priorities or whether it
has truly been tested to failure already, funding priorities
aside. Increased reactogenicity with ISA 720 is highly
likely to be related to the water-in-oil formulation rather
than the antigen.
AMA1-C1/ISA 720
AMA1-C1 combines the 3D7 and FVO strains of AMA1
recombinant protein, expressed in P. pastoris. The com-
bination here was pre-formulated with ISA 720. A Phase
1a study of AMA1-C1/ISA 720 was terminated partway
through enrolment due to a documentation problem
unrelated to this particular vaccine at the pharmacy
where final formulation was conducted. It is difficult to
evaluate the incomplete immunogenicity data that was
obtained, though the short-lived nature of the induced
anti-AMA1 response was notable given the usual depot-
like effect of ISA 720. Degradation in droplet size and
protein integrity was also noted in long-term stability
studies [145]. Both early and delayed local reactions
were seen after vaccination, including an injection site
nodule in one volunteer.
AMA1-FVO (25-545)
In order to compare the reactogenicity and immuno-
genicity of several adjuvants, this Phase 1a study exam-
ined the FVO strain of AMA1 expressed in P. pastoris
and adjuvanted with either alhydrogel, Montanide ISA
720 or AS02. Generally, all three strategies were accep-
tably safe, but AMA1 with ISA 720 or AS02 was more
reactogenic and displayed higher levels of anti-AMA1
antibodies and IFN-g and IL-5 cytokines than with alhy-
drogel [146]. However, due to concerns about whether a
single allele of AMA1 was likely to afford relevant clini-
cal efficacy, clinical development of this AMA1 candi-
date has been discontinued and evolved into the AMA
DiCo ("diversity covering”) project that has not yet
reached clinical trials [1].
AMA-1 “Australia”
In this project E. coli expressed AMA1 was adjuvanted
with Montanide ISA 720. There were low anti-AMA1
antibody responses and only a few volunteers displayed
T cell responses. The reactogenicity profile associated
with Montanide ISA 720, including local pain and
delayed injection site reactions, were also found in this
study [147].
PfCP2.9 (MSP-1 19/AMA-1 chimera)
PfCP2.9 is a fusion protein containing domain III of
AMA1 strain 3D7 and the 19 kDa c-terminal portion of
MSP1 strain K1/FVO, expressed in P. pastoris and adju-
vanted with Montanide ISA 720. Two Phase 1a trials
have assessed the safety, reactogenicity and immuno-
genicity of the vaccine construct at various dosage levels
and vaccination schedules. The first 1a trial, examining
high doses of the vaccine, demonstrated high anti-
PfCP2.9 antibody titres but displayed some local reacto-
genicity [148]. The second Phase 1a trial, assessed the
vaccine at lower doses and with wider gaps in the vacci-
nation schedule. The antibody titres remained high with
reduced reactogenicity, but GIA and IFA activity were
suboptimal and the immunogenicity was markedly lower
than seen in non-human primates [149].
GLURP (85-213)
Anti-GLURP antibodies have been associated with a
reduced risk of clinical disease in those naturally
exposed, and as with MSP3, cytophilic IgG subclasses
are implicated in possible protection. A Phase 1a trial
utilizing a GLURP long synthetic peptide adjuvanted
with either aluminium hydroxide or Montanide ISA 720
showed both a strong cell-mediated and humoral
response, especially for anti-GLURP IgG1. However,
both formulations of the vaccine displayed a dose-
dependent increase in adverse events at the injection
site and 7/18 volunteers in the ISA 720 group did not
receive a third immunization due to predefined
Schwartz et al. Malaria Journal 2012, 11:11
http://www.malariajournal.com/content/11/1/11
Page 11 of 22
withdrawal criteria [150]. Evaluation of GLURP con-
tinues as part of the GMZ2 construct.
Combination vaccines including multiple life-cycle stages
NMRC-M3V-D/Ad-PfCA Prime/Boost & NMRC-M3V-Ad-PfCA
These approaches are DNA-based vaccination combin-
ing the CS pre-erythrocytic antigen with the AMA1
blood-stage antigen (now known also to also be
expressed in other stages of the life-cycle). The initial
strategy was to use DNA encoding CS and AMA1 pro-
teins to prime, then boost with adenovirus 5 vectors
expressing the same antigens. Publication of the results
of the Phase 2a challenge study is awaited [151]. A
Phase 1 trial was conducted in US with adenovirus 5
vectors encoding CS and AMA1. Very high frequencies
of CD8+ T cells were induced [152], but no sterile pro-
tection was afforded in a follow-on Phase 2a trial using
the CS component alone [153]. These approaches con-
firm the promise of Ad5 for induction of CD8 responses
in humans. Some refinements to this approach are in
pre-clinical development [1].
CS, AMA1 virosomes (PEV301,302)
Synthetic peptides were manufactured representing frag-
ments of malaria proteins thought to be good immune
targets. These are displayed as phospatidylethanolamine
(PE)-peptide conjugates on the surface of IRIVs (immu-
nopotentiating reconstituted influenza virosomes).
PEV301 is the virosome with the synthetic CS protein
conjugate UK39, and PEV302 virosome has the synthetic
AMA1 protein conjugate AMA149-C1. IRIVs have
already been used for licensed influenza and hepatitis A
vaccines and, in various guises, can deliver multiple anti-
gens to focus on CD4, CD8 T cell or antibody
responses. A Phase 1a study in healthy malaria naïve
adults demonstrated that volunteers immunized with a
mix of both PEV301 and PEV302 developed anti-
AMA149-C1 and anti-UK39 antibody titres [154].
Further immunogenicity studies on the PEV301 portion
of the vaccine revealed induced in vitro inhibition of
sporozoite migration and hepatocyte invasion [155]. In a
Phase 2a experimental sporozoite challenge trial in
malaria non-immune Caucasian volunteers, vaccine-
related partial but modest protection against sporozoite
challenge was observed in terms of a delay in time to
parasitaemia [156], although no sterile protection was
observed. A recently completed Phase 1b vaccine trial in
semi-immune Tanzanian adults and children confirmed
the safety and immunogenicity of the platform. In addi-
tion, an exploratory analysis showed a reduced incidence
of clinical episodes of malaria. Whilst interesting this
requires confirmation in field efficacy studies [157].
There has been a change of ownership of the biotech
company with potential implications for the future
application of this promising technology to malaria.
Discontinued combination vaccines including multiple
life-cycle stages
Spf66
Spf66 is a vaccine candidate developed in Colombia in
the late 1980s. It is a synthetic peptide consisting of CS
and merozoite surface protein 1 (MSP1) epitopes adju-
vanted with alum, and more recently tested with QS-21.
Several studies in multiple Phases and countries have
assessed this vaccine and while overall the vaccine was
felt to be safe, the immunogenicity and vaccine efficacy
have been relatively low [158]. Phase 3 studies in South
America reported a vaccine efficacy of 28% (95%CI 18-
37) for clinical malaria [159], but the African and Asian
studies taken together failed to show useful efficacy for
this vaccine [160-169]. There was much debate about
the interpretation of the South American results because
of the many differences in trial design between the first
studies and those in Africa and Asia. This is an impor-
tant example of the fact that malaria field efficacy data
should be obtained using standardized consensus case
definitions, endpoints and trial designs in a variety of
epidemiological settings among various age groups, and
then be applied only to the settings and age groups in
which it was obtained, because of the major heterogene-
ities of malaria epidemiology, immunity and vaccine effi-
cacy. When vaccine efficacy varies from trial to trial,
manufacturing consistency between vaccine lots could
be a contributory factor.
RTS,S/AS02 (CS) and FMP-1/AS02 (MSP1)
Combination of RTS,S with other promising approaches
has long been one stated aim of the RTS,S development
programme. In this Phase 1/2a trial, researchers conco-
mitantly administered FMP-1/AS02 and RTS,S/AS02A.
Efficacy of RTS,S/AS02 was similar in co-administration
with FMP1/AS02 compared to RTS,S alone. This indi-
cated that there was no detectable immunological inter-
ference between the two components, and that FMP1
gave no protection in the challenge model as detected
by microscopy [170].
Sexual stage vaccines
Currently there are a few sexual stage vaccines in preclini-
cal development and at least one Phase 1 trial is underway.
As the vaccines are intended to block the life-cycle in Ano-
pheline mosquitoes, vaccine efficacy needs to be measured
as a reduction in community level transmission of malaria,
through cluster randomized trials. Due to the logistic chal-
lenges with conducting large cluster randomized trials, the
availability of data for decision-making earlier in the devel-
opment pathway could greatly facilitate progress with
these vaccines. Intermediate proof-of-principle efficacy
trials may be possible with the emphasis on demonstrating
a reduction in infectivity of humans for mosquitoes. A
valuable membrane-feeding assay (MFA) enables
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investigators to assess the ability of sera raised against sex-
ual stage antigens to reduce infection of mosquitoes on
exposure to gametocyte-infected blood, but the link
between immune responses in individuals and effect on
transmission is not known. Efforts to qualify, and if possi-
ble to validate, this assay will be important for vaccine
development.
Given the disappointing results of many blood stage
vaccine projects, and the emphasis on malaria eradica-
tion as a long-term aim by some funders, sexual and
mosquito stage vaccine R&D funding may well increase
over the next 5-10 years.
Previous clinical trials of sexual stage vaccines that
have been discontinued involve ookinete antigens Pfs25
from P. falciparum and Pvs25 from P. vivax. Phase 1
studies examined the antibody response to the vaccine
as well as activity in MFA. Saccharomyces cerevisiae
expressed Pvs25, adjuvanted with alhydrogel, elicited
low titre anti-Pvs25 antibodies and little transmission
blocking activity [171]. A second Phase 1 study examin-
ing Pvs25 and Pfs25 adjuvanted with Montanide ISA 51
induced some antibody response and transmission
blocking activity. The study was stopped due to unac-
ceptable reactogenicity most likely related to the adju-
vant [172]. In both studies and in pre-clinical work by
the same group there is a consistent correlation between
titre of anti-Pfs25 antibody and MFA activity [173].
Two of the sexual stage vaccine projects in preclinical
development are based on the Pfs25 antigen. Preclinical
studies in mice have shown that when Pfs25 is chemi-
cally conjugated to recombinant Pseudomonas aerugi-
nosa ExoProtein A (EPA) and adjuvanted with
alhydrogel, both the anti-Pfs25 antibody response and
transmission blocking activity are significantly higher
than with Pfs25/alhydrogel alone [174,175]. A Phase 1
clinical trial of this vaccine candidate began in the latter
part of 2011 [176]. Given that sexual stage and mos-
quito antigen vaccines will need to be administered
across a wide age range commensurate with the human
infectious reservoir in each setting, robust safety is a key
feature of the desired target product profile. It is there-
fore highly encouraging that the pre-clinical studies with
Pfs25-EPA indicate that alhydrogel may be sufficient as
an adjuvant. Avoiding the many challenges associated
with novel adjuvants, where possible, may be advisable
for this group of vaccines.
Preclinical studies examining multimeric Pfs25 self-
conjugates also showed an increase in anti-Pfs25 anti-
body levels and reduction of oocyst numbers in the
mosquito midgut [13].
Plasmodium vivax vaccine projects
Control of mosquito vectors that support P. vivax has
proven more challenging than P. falciparum in many
settings, and P. vivax transmission may persist after P.
falciparum has been eliminated because of its capacity
to cause relapse from hypnozoites in the liver. Field trial
design is complicated by the fact that P. vivax vaccine
evaluation will most likely occur in co-endemic settings
and the fact that distinguishing hypnozoite reactivation
from new infections is not straightforward. Additionally
the sporozoite challenge model is less well established
for P. vivax, partly because culture of P. vivax gameto-
cytes is problematic.
As with sexual stage and mosquito antigen projects, P.
vivax is likely to receive additional R&D funding in the
next 5-10 year cycle, particularly if P. falciparum trans-
mission, morbidity and mortality continue to fall. Thus
although there is a little clinical activity to report now,
this is likely to change [177].
VMP001/AS01B
VMP001/AS01B is currently the only vaccine in clinical
evaluation that is designed to protect against P. vivax.
In contrast to P. falciparum, the immunodominant B
cell epitopes exhibit dimorphism in P. vivax. VMP001
includes the repeat region from the two alleles (VK210
and VK247) as well as N and C terminal fragments. It is
an E. coli expressed recombinant protein adjuvanted
with AS01. A Phase 1/2a challenge trial occurred in US
volunteers at the end of 2010 [14].
Discussion and Conclusion
Over two decades on from the first clinical trials of vac-
cines for malaria, much has been learned about the
pipeline from discovery research in the laboratory to
successful conduct and analysis of large-scale field stu-
dies (see table 1), and one product is undergoing Phase
3 studies with a view to licensure. In this period, sub-
stantial progress has been made in evaluating many anti-
gens and scientists have learned much about the need to
meet requirements of developers in establishing clear
product profiles.
Compared with other infectious diseases of major glo-
bal importance such as HIV and tuberculosis, malaria
vaccine research is facilitated by the availability of a clin-
ical challenge model and a high attack rate in endemic
areas, enabling definitive assessment by human experi-
mentation for vaccines that prevent infection. There is
consensus for testing the efficacy of pre-erythrocytic
vaccines in sporozoite challenge studies, and an emer-
ging consensus that some evidence of effect as evi-
denced by a degree of sterile protection or at least a
reduced parasite growth rate is required as a pre-condi-
tion for moving asexual stage vaccines to expensive
large-scale clinical trials, as other measures such as
growth-inhibitory assays have yet to fulfill their promise
as surrogate markers of protection. WHO is facilitating
a harmonization process for sporozoite challenge trials
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with consensus Standard Operating Procedures and
documents available to guide design and conduct of
such trials.
There is now consensus on many of the case defini-
tions, endpoints and best analytical methods for mea-
surement of reduction of morbidity conferred by pre-
erythrocytic vaccines [178]. WHO has requested that
data on multiple episodes of malaria, and time at risk, is
presented divided into time periods to enable evaluation
of long-term follow-up data [179], as impact on multiple
episodes of malaria is the most important clinical/out-
patient malaria endpoint from the public health and pol-
icy perspective. Methodological areas which remain the
subject of ongoing work include: statistical methods for
examining the duration of protection of vaccines taking
into account the major but unmeasured heterogeneities
of risk; case definitions and endpoints for blood-stage
vaccine efficacy trials; trial designs for evaluation of
reduction in infectivity of humans for mosquitoes.
Profiles for products targeted to reduce the global
burden of malaria have focused on the desirability of
reducing mortality and morbidity in vulnerable groups
of young children and pregnant women [180] living in
endemic areas, whereas targets for military and traveler
populations focus on complete prevention of infection,
even for relatively short periods after vaccination. It is
highly likely that different immune mechanisms operate
to prevent infection or modify disease but in neither
case is the critical protective immune response for these
target groups known or understood. Promising effects of
RTS,S have encouraged investigators and funding agen-
cies to raise the longer term target product threshold
efficacy to the order of 80% for second generation pro-
ducts, yet still with a longer term “gold standard” aim
for complete protection from clinical disease.
More recently, thanks to some successful malaria
reduction campaigns in parts of Africa and the critical
advocacy of Bill and Melinda Gates, the malaria com-
munity is considering the research and other require-
ments for a strategy leading to eventual eradication of
malaria [11]. Of course this has always been seen as the
ultimate goal but priority in the past four decades has
been given to reducing the disease burden in regions
with highest endemicity. The re-emergence of debate on
eradication has not reduced the priority that scientists
give to vaccines for potential impact, but has caused
vaccines to be seen through another lens for their
potential to reduce disease transmission. Vaccines
Table 1 Lessons learned in terms of safety, immunogenicity, efficacy and trial methodology from malaria vaccine
research over the last 5-10 years
Safety Reactogenicity is higher with water-in-oil emulsions (e.g. ISA 720) when compared to marketed adjuvants (alhydrogel) or a
marketed virosomal platform.
Safety and reactogenicity in semi-immune populations living in endemic areas has not been higher than in naïve populations, and
is often lower.
Safety and reactogenicity in young children has not been worse than in adult populations
Immunogenicity DNA alone is poorly immunogenic
Oil in water emulsions (AS01, AS02) and water in oil emulsions (ISA 720, ISA51) are more immunogenic than alhydrogel for
recombinant monomeric protein
In general, there is little induction of CD8 cells in humans (with the exception of certain adenovirus containing regimens)
In general, there has been little clinically significant interference between the malarial antigen and EPI vaccine antigens
Efficacy Only RTS,S-based vaccines have repeatedly shown efficacy to reduce morbidity in endemic areas
Highly polymorphic blood-stage antigens have tended to lead to allele-specific efficacy, but poor efficacy against the population
of circulating strains
Multiple episodes of malaria takes priority over time to first episode for public health assessment in clinical malaria vaccine trials.
Methodology Demonstration of effect in in vitro studies (growth-inhibition assay in particular) or animal studies have not been shown to
correlate well with efficacy results in the field
Human challenge studies (Phase IIa trials) have been validated for the screening of pre-erythrocytic vaccines by the RTS,S results
It is agreed that every Phase IIb/III vaccine trial design includes a commercialized vaccine that will benefit the control group as
comparator and that any trial subject receives at least the standard package of preventive measures (LLIN and others)
implemented in the country.
Methodological and ethical issues would arise in testing of new malaria vaccines in the field if a licensed malaria vaccine had
become a standard preventive measure in a given setting.
Methodological and feasibility issues are arising to test new vaccines in the field because malaria morbidity is considerably
decreasing in areas where trial sites are in place.
There is as yet no formal trial design to assess the efficacy of sexual stage and mosquito antigen vaccines prior to large scale
cluster randomized trials; specific baseline epidemiological studies are required for sample size calculations and trial design for
possible Phase IIb trials in this area
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directed against any stages of the parasite could have
impact on transmission, with sexual stage vaccines tar-
geting only this activity, and vaccines against mosquito
gut having similar potential.
There was some concern two decades ago that vac-
cines designed to prevent immunity in travelers or the
military may be of limited benefit to children of ende-
mic areas since immunity against malaria is known to
be species and stage specific. It is believed that a pre-
erythrocytic vaccine designed to prevent infection in a
non-immune individual would need to be highly effec-
tive for impact (well over 80% sterile protection) since a
single parasite reaching the blood stream could lead to
lethal infection. This however may not be true for semi-
immune individuals when an effect of reducing the bur-
den of parasites reaching the bloodstream may be of
benefit in reducing uncomplicated malaria and severe
morbidity. The better than expected effects of RTS,S
vaccine in children of endemic areas support this
hypothesis, and suggest that this vaccine could be
achieving in some of the population the desired goal of
converting the immune status of infants of endemic
areas from that of a newborn to that of a three year old
child who is protected, albeit incompletely, from clinical
disease despite recurrent infection (concomitant
immunity).
Early success with the pre-erythrocytic vaccine RTS,S
and the call for malaria eradication have led some fun-
ders to reduce priority and funding for vaccines directed
against blood stages. Most in the field argue that the
considerable evidence for protection directed against
blood stages, such as passive transfer experiments, vali-
date the approach of seeking to combine the best candi-
dates from more than one stage. A major consideration
is to determine criteria for advancing particular
candidates.
Various factors have been used to decide on moving
candidates to clinical trials but as none has proved reli-
able, better ways of making this assessment and down-
selection are needed. Animal models are not optimal
and immune responses in rodents or non-human pri-
mates have not so far proved to be reliable indicators.
Highly variable antigens with multiple alleles are
obviously targets of the immune response under natural
challenge, and vaccine studies of AMA-1 and MSP 2
suggest that allele-specific effects can be achieved. How-
ever, the task of making a construct that would induce
protection against a multitude of variants could be
insurmountable. On the other hand, invariant antigens
that are critical for invasion could be good targets if
they could be made immunogenic. There is growing
consensus that in order to progress an antigen to field
trial stage, there is a requirement for the candidate to
have demonstrable impact on parasite growth in non-
immune individuals. Recent advances in antigen delivery
systems using viral like particles, novel adjuvants, and
alternate delivery systems, such as recombinant viral
delivery and heterologous prime boosting have demon-
strated capacity to induce effective responses that are
not seen following natural infection and treatment or
recovery.
Advances in technology have now provided proof of
principle (in other systems as well as malaria) that the
combination of priming with DNA and boosting by viral
delivery, or priming and boosting with two different
viral delivery systems can induce protection in a propor-
tion of individuals. Studies of protected and non-pro-
tected individuals may enhance understanding of the
critical immune response and give a guide to correlates
of protection that may then potentially be inducible
with simpler regimens. Malaria vaccine researchers fol-
low developments in HIV and tuberculosis with great
interest, considering the similar challenges of under-
standing the non-sterilising clinical immunity that
occurs at stages of these three diseases. All share the
goal of understanding mechanisms for inducing long-
lived immunological memory and how new and
improved technologies could achieve this goal
With regard to adjuvant selection, the ICC-1132 pro-
ject described in this review [65-68] serves as a useful
case study of some general points. First, alum-adjuvanta-
tion has been repeatedly demonstrated to be inadequate
for inducing the desired response to monomeric recom-
binant malaria proteins. However if alum-adjuvantation
were to be sufficient in specific cases this would prob-
ably represent the best adjuvant approach in many ways,
and there is some hope that with increased immuno-
genicity of protein conjugation or particulate technolo-
gies, alum-adjuvantation might suffice in some cases.
Secondly, promising immunogenicity in mice, as was
seen with ICC-1132, has often not translated to the
clinic. Thirdly the strongest clinical experience with
adjuvants is with GSK’s proprietary adjuvants such as
AS02 and AS01. Given the issues with access to these
proprietary adjuvants, groups have often opted for use
of water-in-oil adjuvants such as ISA 720 or ISA 51 and
these tend to give good results in pre-clinical experi-
ments. However, an unfavourable combination of issues
with chemical modification of antigens that can com-
promise stability, a lack of consistency for bedside for-
mulation and at times unacceptable local reactogenicity
have tended to terminate development of many water-
in-oil formulations in the malaria field. There is suffi-
cient experience with these water-in-oil emulsions now
to recommend alternate formulations. Thus access to
sufficiently potent adjuvants suitable for clinical use and
without proprietary limitations remains a key rate-limit-
ing factor in malaria vaccine development.
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Many lessons have been learned about the long pro-
cess of establishing field trial sites, gaining regulatory
approval, establishing Ethics Committees, and complet-
ing analysis. Incidence of malaria invariably falls with
the intensive surveillance required for clinical analysis in
well-monitored field sites and trial sample sizes are
necessarily increased considering the decreased inci-
dence of malaria for test and control groups, when gold
standard control measures are applied for all partici-
pants. In addition, malaria transmission has fallen in the
region of several field trial sites, probably due to the
success of national malaria control programmes. Investi-
gators have recognized the need to be prepared to
increase the duration or geographical scope to achieve
the required numbers of enrolments. It is essential to
develop local regulatory and ethics capacity for local
trials. Communication is critical for informing partici-
pants and communities about the goals of studies that
in many cases would be better described as “experimen-
tal medicine” or “trials in humans” rather than “vaccine
trials”, in order not to raise artificially high expectations
of outcomes. Establishing these basic supports is very
important for the large number of future trials to exam-
ine various combinations and the duration of efficacy.
So far there has been no evidence of disease enhance-
ment, but researchers must continue to be vigilant, and
also be aware of potential rebound morbidity following
temporary interruption of clinical infections.
Considering the devastating impact of the disease, glo-
bal resource allocation has been modest, particularly
now that the RTS,S success confirms that malaria vacci-
nation can reduce paediatric morbidity in the field. In
the years ahead it will be appropriate to aim for a vac-
cine with 80% or higher efficacy and substantial impact
on transmission as envisaged by the malaria vaccine
technology roadmap, as a 2025 goal, and malaria eradi-
cation R&D agenda initiatives.
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